GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Perspective Therapeutics
Perspective Therapeutics is a biotech company specializing in targeted radiation therapy for cancer. Its stock price is a venture bet on the success of its scientific platform. The chart reflects high volatility and dependence on clinical trial data.
Share prices of companies in the market segment - Oncology platforms
Perspective Therapeutics develops targeted alpha therapy and diagnostic tools for the treatment and imaging of oncological diseases. We have classified it as an "Oncology Platform." The chart below shows how investors value companies working at the forefront of nuclear medicine.
Broad Market Index - GURU.Markets
Perspective Therapeutics develops targeted alpha therapy and diagnostic tools for the treatment and imaging of oncology diseases. It is a component of the GURU.Markets index. The chart below shows the market. See how this company's stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
CATX - Daily change in the company's share price Perspective Therapeutics
For Perspective, an oncology company, change_co is a measure of innovation volatility. Daily fluctuations reflect news about clinical trials of its radiopharmaceutical platform. This metric forms the basis for biotech company analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology platforms
Perspective Therapeutics, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with the performance of CATX, which focuses on radiopharmaceuticals, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Perspective is an oncology company developing radiopharmaceuticals for the diagnosis and treatment of cancer. The biotech sector is extremely volatile, and Perspective's story is a prime example. The chart below reflects the average fluctuations in this industry, providing context for evaluating the company's stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Perspective Therapeutics
For Perspective Therapeutics, the year-over-year trend is a story about developing a new approach to cancer treatment—targeted radiation therapy. Its 12-month market cap depends entirely on progress in clinical trials of its drugs, which deliver alpha particles directly to tumors. Success could lead to a breakthrough in nuclear medicine.
Annual dynamics of market capitalization of the market segment - Oncology platforms
Perspective Therapeutics is a biotech company developing a new class of targeted radiotherapy for cancer treatment. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the high risks inherent in this sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Perspective Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Perspective Therapeutics
The value of Perspective, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but news about the progress of clinical trials of its radiopharmaceuticals for cancer diagnostics and treatment, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Oncology platforms
Perspective Therapeutics develops targeted radiotherapy for cancer treatment. This is one of the most advanced areas in oncology. The chart below reflects investor confidence in the potential of smart radiopharmaceuticals, highlighting the overall sentiment in this high-tech and risky segment of the biotech market.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Perspective Therapeutics develops cutting-edge radiation therapy for cancer. It's a company at the forefront of medical science. Its stock price is driven by the potential of its technology platform and clinical trial results, not by general market trends. It's betting on a revolution in oncology.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Perspective Therapeutics
Shares of Perspective Therapeutics, which develops radiopharmaceuticals for cancer diagnostics and treatment, are extremely volatile. Weekly price movements depend on news about clinical trials and progress in this cutting-edge field of oncology. The chart below shows how short-term scientific developments and investor expectations shape the company's value.
Weekly dynamics of market capitalization of the market segment - Oncology platforms
How unique is Perspective Therapeutics' performance in the biotech sector? This chart compares the weekly stock price movements of this radiopharmaceutical company with the overall trend. This helps us understand whether its sharp movements are a unique reaction to news in this cutting-edge field or reflect general sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Perspective Therapeutics develops targeted therapy for cancer. This chart shows how out of sync its weekly performance is with the market. Its stock moves are driven by news about clinical trials and scientific progress, not the overall economic situation.
Market capitalization of the company, segment and market as a whole
CATX - Market capitalization of the company Perspective Therapeutics
Perspective Therapeutics' valuation on the chart is a bet on its cutting-edge approach to cancer treatment using targeted radiation therapy. The company's market cap hinges on the success of its clinical trials, which combine precise diagnostics with "molecular irradiation" of tumors. The trend illustrates hopes for a breakthrough in nuclear medicine.
CATX - Share of the company's market capitalization Perspective Therapeutics within the market segment - Oncology platforms
Perspective Therapeutics (formerly Isoray) is building its market share by developing and commercializing targeted alpha-therapy for cancer treatment. Its market capitalization reflects the potential of this cutting-edge approach in oncology.
Market capitalization of the market segment - Oncology platforms
Here's a chart of the total market capitalization of biotech companies developing radiopharmaceuticals. Perspective Therapeutics is one of the players in this promising area of oncology. The chart shows how the market values the "smart bomb" technology, which delivers radiation directly to tumors.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart represents the market valuation of a new approach to fighting cancer called "theranostics." Perspective Therapeutics' market cap reflects its belief in its ability to simultaneously diagnose and treat tumors. The line shows how personalized medicine is shaping its potential share of the future of oncology.
Book value capitalization of the company, segment and market as a whole
CATX - Book value capitalization of the company Perspective Therapeutics
Perspective Therapeutics' book value represents its scientific capital. The chart below reflects the valuation of its targeted alpha therapy platform, designed to precisely destroy cancer cells. The pipeline's growth signals progress in developing this cutting-edge treatment and raising research funds.
CATX - Share of the company's book capitalization Perspective Therapeutics within the market segment - Oncology platforms
Perspective Therapeutics's core assets include its laboratories and manufacturing facilities for developing a new class of radiopharmaceuticals for cancer diagnostics and treatment. The chart reflects its share of this unique and complex scientific infrastructure, which forms the physical basis for targeted radiotherapy.
Market segment balance sheet capitalization - Oncology platforms
Below you can see the overall book value of the biotech sector. Against this backdrop, Perspective Therapeutics, which develops radiopharmaceuticals, is capital-intensive. Working with radioactive isotopes requires specialized and expensive laboratories and manufacturing facilities.
Book value of all companies included in the broad market index - GURU.Markets
Perspective Therapeutics develops radiopharmaceuticals for the diagnosis and treatment of cancer. The company's assets are not hospitals, but patents, laboratories, and manufacturing facilities for creating these "smart bombs" that locate and destroy tumors in real life.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Perspective Therapeutics
Perspective Therapeutics' balance sheet is its cash and patents. Its market capitalization is a bet on its "radioactive drug" technology. The MvsBCap_Co chart shows how much the "dream" of targeted cancer treatment is worth compared to the company's actual assets.
Market to book capitalization ratio in a market segment - Oncology platforms
Perspective Therapeutics develops radiopharmaceuticals for cancer diagnostics and treatment. Its value lies in its scientific platform. The chart shows the high speculative market valuation of its innovative approach, which combines imaging and therapy.
Market to book capitalization ratio for the market as a whole
Perspective Therapeutics (formerly Isoray) specializes in the development and commercialization of targeted alpha-therapy for cancer. The company's value lies in its scientific platform and potential to transform approaches to cancer treatment. This chart illustrates why investors are willing to pay a premium for innovative approaches to drug discovery.
Debts of the company, segment and market as a whole
CATX - Company debts Perspective Therapeutics
Perspective Therapeutics (CATX), a company developing radiopharmaceuticals for cancer diagnostics and treatment, is using debt to finance its cutting-edge platform. This chart shows how the company is raising capital for clinical trials of its innovative products. In this field, debt is an investment in the future of personalized oncology.
Market segment debts - Oncology platforms
Perspective Therapeutics is developing a new approach to cancer treatment, combining diagnostics and therapy using radioisotopes. This is a cutting-edge field in oncology. This chart shows how the clinical-stage biotech company is funding its complex and capital-intensive theranostics research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Perspective Therapeutics
Perspective Therapeutics develops targeted radiotherapy for cancer treatment. This chart illustrates the company's reliance on external funding. In the cutting-edge field of nuclear medicine, where research and production of radioisotopes are extremely expensive, high debt is a huge risk, dependent entirely on clinical success and regulatory approval.
Market segment debt to market segment book capitalization - Oncology platforms
Perspective Therapeutics develops targeted radiotherapy for cancer treatment. This is a cutting-edge area of oncology, requiring investment in R&D and clinical trials. The chart shows how the company's debt load compares to the market capitalization and risks of the overall biotech sector.
Debt to book value of all companies in the market
Perspective Therapeutics (CATX) develops targeted radiotherapy for the diagnosis and treatment of cancer. This is at the forefront of nuclear medicine. This chart shows the overall market leverage. It provides an excellent backdrop for understanding why companies like CATX avoid debt during the R&D phase by raising specialized capital.
P/E of the company, segment and market as a whole
P/E - Perspective Therapeutics
This chart shows the valuation of Perspective Therapeutics, a company developing targeted radiation therapy for cancer treatment. There is no price-to-earnings ratio. The valuation is based on the potential of its approach, which allows for the delivery of radiation directly to tumor cells. The company's performance depends on progress in clinical trials of its drugs.
P/E of the market segment - Oncology platforms
This chart shows the average P/E ratio for biotech companies. For Perspective Therapeutics, a radiopharmaceutical company, it serves as a backdrop. It reflects the overall level of investor faith in breakthrough oncology technologies, providing context for evaluating its unique platform.
P/E of the market as a whole
Perspective Therapeutics (formerly Isoray) develops and commercializes radiation therapies for the treatment of cancer, particularly prostate cancer. The company specializes in brachytherapy. This chart, reflecting overall sentiment, helps understand how investors view companies operating in established but important areas of oncology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Perspective Therapeutics
Perspective Therapeutics is a radiopharmaceutical company developing drugs for targeted cancer diagnostics and therapy. This approach uses radioactive isotopes to seek out and destroy cancer cells. This graph reflects expectations for the future of nuclear medicine. The assessment depends on the success of its platform and clinical trials of its candidates.
%20P%2FE%20Perspective%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Perspective-Therapeutics&v=1772573832347 "Chart of the company's future (projected) P/E Perspective Therapeutics")
Future (projected) P/E of the market segment - Oncology platforms
Perspective Therapeutics develops targeted alpha therapy for cancer treatment using radioisotopes to destroy tumor cells. This chart reflects the company's long-term profitability expectations. It demonstrates how highly the market values their innovative approach to radiopharmaceuticals and the potential for developing new treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-platforms&v=1772573832418 "Future (projected) P/E graph of the market segment - Oncology platforms")
Future (projected) P/E of the market as a whole
Perspective Therapeutics develops radiopharmaceuticals for the diagnosis and treatment of cancer. This is a cutting-edge field of oncology. The company's success depends on clinical results. This market expectations chart reflects investor appetite for risky biotechnologies. Market optimism facilitates raising capital for such breakthrough research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772573832437 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Perspective Therapeutics
Perspective Therapeutics is a radiopharmaceutical company developing drugs for the diagnosis and treatment of cancer. Its approach utilizes radioactive isotopes to precisely target tumor cells. Financial results reflect the development costs of this cutting-edge oncology platform.
Profit of companies in the market segment - Oncology platforms
Perspective Therapeutics develops targeted radiation therapy for cancer, delivering radiation precisely to tumors. This is a promising area of oncology. This graph illustrates how scientific breakthroughs in treatment methods are shaping the future of oncology, with investments in new platforms like this one determining the future profitability of the entire sector.
Overall market profit
Perspective Therapeutics is a radiopharmaceutical company developing targeted therapies for the diagnosis and treatment of cancer. This is a cutting-edge field of medicine. The company's success depends on clinical data and the innovation of its platform. Its history is unrelated to the general economic cycles that shape the overall picture in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Perspective Therapeutics
Perspective Therapeutics is developing targeted alpha therapy for cancer treatment, combining radioisotopes with antibodies. This schedule reflects expectations, which are entirely dependent on the success of its platform in clinical trials. The potential of this cutting-edge technology for the precise destruction of cancer cells shapes the outlook.
%20profit%20of%20the%20company%20Perspective%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Perspective-Therapeutics&v=1772573832566 "Graph of future (projected) profit of the company Perspective Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology platforms
Perspective Therapeutics is developing targeted alpha therapy for cancer treatment. This chart shows the revenue forecast for the entire oncology platform sector. It reflects expectations for breakthroughs in radiopharmaceuticals. This background is important for assessing the potential of Perspective Therapeutics' innovative approach to cancer treatment.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-platforms&v=1772573832595 "Graph of future (predicted) profits of companies in a market segment - Oncology platforms")
Future (predicted) profit of the market as a whole
Perspective Therapeutics develops radiopharmaceuticals for cancer diagnostics and treatment. This cutting-edge field requires significant investment. The company's future depends on the success of its technologies and the availability of capital. The overall economic climate, as illustrated here, influences investor willingness to invest in long-term, high-risk medical projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772573832632 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Perspective Therapeutics
Perspective Therapeutics develops and utilizes targeted alpha therapy for cancer treatment. This approach uses radioactive particles to precisely destroy tumor cells. This chart shows how investors view this cutting-edge oncology platform, which has the potential to become a new standard of care for certain types of cancer.
P/S market segment - Oncology platforms
Perspective Therapeutics (formerly Isoray) is a radiopharmaceutical company developing and commercializing targeted therapies for cancer treatment. The company uses alpha-emitting isotopes to precisely destroy tumor cells. This chart shows the average valuation for the sector, helping to understand how the market views this cutting-edge oncology technology.
P/S of the market as a whole
Perspective Therapeutics is a radiopharmaceutical company developing targeted drugs for cancer diagnosis and treatment. The company's approach involves delivering radiation directly to tumor cells. This market valuation chart helps understand the premium investors are paying for the biotech's potentially revolutionary, yet risky, revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Perspective Therapeutics
Perspective Therapeutics develops radiopharmaceuticals for the diagnosis and treatment of cancer. Currently in the clinical stage, it is evaluated based on its future potential. This graph reflects investors' confidence in its innovative approach to targeted therapy and future commercial success.
%20P%2FS%20Perspective%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Perspective-Therapeutics&v=1772573832783 "The graph of the company's future (projected) P/S Perspective Therapeutics")
Future (projected) P/S of the market segment - Oncology platforms
Perspective Therapeutics is a radiopharmaceutical company developing targeted therapies for cancer diagnostics and treatment. This chart compares market expectations for its future revenue with other oncology platforms. This valuation reflects investor confidence in its approach, which combines therapeutics and diagnostics (theranostics).
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-platforms&v=1772573832822 "Future (projected) P/S market segment graph - Oncology platforms")
Future (projected) P/S of the market as a whole
Perspective Therapeutics is developing a new approach to cancer treatment using radioactive isotopes to target tumors. This is at the forefront of nuclear medicine. Market optimism, evident in this chart, is helping companies like these attract the investment needed to advance this complex and promising technology through clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772573832851 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Perspective Therapeutics
Perspective Therapeutics is a radiopharmaceutical company developing drugs for the diagnosis and treatment of cancer. Its approach utilizes radioactive isotopes to precisely target tumors. Currently in clinical trials, its revenue comes from partnerships and grants. The chart reflects funding for this cutting-edge oncology technology.
Sales of companies in the market segment - Oncology platforms
Perspective Therapeutics develops and commercializes drugs for radiopharmaceutical diagnostics and cancer therapy. Its approach uses radioisotopes to precisely detect and specifically destroy cancer cells. This graph illustrates the growing interest in targeted radiotherapy, which is becoming one of the most promising areas in oncology.
Overall market sales
Perspective Therapeutics develops radiation therapy for cancer. This is a high-tech field of medicine, and the company's success depends on research results. The economic situation reflected here is indirectly important, as it affects the overall investment climate in the biotech sector and the funding of clinical trials.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Perspective Therapeutics
Perspective Therapeutics is a radiopharmaceutical company developing drugs for targeted cancer diagnostics and therapy. Its approach utilizes radioactive isotopes to detect and destroy cancer cells. This chart reflects analysts' confidence in the potential of radiopharmaceuticals and the success of the company's clinical programs.
%20sales%20of%20the%20company%20Perspective%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Perspective-Therapeutics&v=1772573833105 "Schedule of future (projected) sales of the company Perspective Therapeutics")
Future (projected) sales of companies in the market segment - Oncology platforms
Perspective Therapeutics is developing targeted alpha therapy for the treatment of oncology diseases. This chart shows the overall outlook for the oncology platform sector. It allows one to assess the potential of the company's approach, which uses alpha-emitting isotopes to precisely destroy cancer cells, and how it compares to other treatment methods.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-platforms&v=1772573833137 "Schedule of future (projected) sales of companies in the market segment - Oncology platforms")
Future (projected) sales of the market as a whole
Perspective Therapeutics develops radiopharmaceuticals for the diagnosis and treatment of cancer. This chart, reflecting investments in oncology, is important to the company. Developing this cutting-edge technology requires significant capital, and investor confidence, driven by the overall economic climate, determines the availability of funding.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772573833160 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Perspective Therapeutics
Perspective Therapeutics is a radiopharmaceutical company developing targeted drugs for cancer diagnosis and treatment. Its theranostics approach allows for simultaneous imaging and treatment of tumors. This graph reflects its investment in cutting-edge science that has the potential to change the paradigm in oncology, transforming diagnostic tools into therapeutic ones.
Market segment marginality - Oncology platforms
Perspective Therapeutics develops targeted radiotherapy for cancer. Their approach involves delivering radioactive isotopes directly to tumor cells, minimizing damage to healthy tissue. This chart reflects their investment in this cutting-edge oncology platform, which has significant therapeutic and commercial potential.
Market marginality as a whole
Perspective Therapeutics is developing a new approach to cancer treatment, combining diagnostics and targeted alpha therapy. The overall profitability picture is irrelevant to them. Their value lies in the potential of their scientific platform. Success depends entirely on the results of clinical trials and the ability of their technology to accurately find and destroy tumors.
Employees in the company, segment and market as a whole
Number of employees in the company Perspective Therapeutics
Perspective Therapeutics is a radiopharmaceutical company developing targeted therapies for cancer treatment. This chart shows the team of scientists working in this complex and promising area of oncology. The growth in staff reflects progress in clinical trials and investments in manufacturing capacity.
Share of the company's employees Perspective Therapeutics within the market segment - Oncology platforms
Perspective Therapeutics is developing targeted alpha therapy for cancer treatment, using radioactive isotopes to precisely destroy tumor cells. This chart shows the percentage of leading nuclear medicine scientists the company attracts. It's a testament to its work at the forefront of oncology and the team behind the next generation of radiopharmaceuticals.
Number of employees in the market segment - Oncology platforms
Perspective Therapeutics develops radiopharmaceuticals for cancer diagnosis and treatment. This chart shows the growth of employment in this cutting-edge field of oncology. The increase in the number of scientists and radiochemists reflects the advancement of this approach, which enables the simultaneous visualization and destruction of tumor cells with high precision.
Number of employees in the market as a whole
Perspective Therapeutics (formerly Isoray) specializes in the development and production of radioisotope therapies for the treatment of cancer, particularly prostate cancer. This is a cutting-edge nuclear medicine company. This chart shows overall employment, and high-tech companies like Perspective represent a knowledge-intensive sector that requires unique specialists in physics, chemistry, and medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Perspective Therapeutics (CATX)
Perspective Therapeutics, Inc. is an oncology company developing targeted radiation therapy. Its valuation is based almost entirely on the scientific potential of its platform. This chart demonstrates a model where intellectual capital dominates. A small team of scientists can create technology worth hundreds of millions of dollars, resulting in an extremely high valuation per employee.
%20of%20the%20company%20Perspective%20Therapeutics%20(CATX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Perspective-Therapeutics-CATX&v=1772573833506 "Chart of market capitalization per employee (in thousands of dollars) of the company Perspective Therapeutics (CATX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology platforms
Perspective Therapeutics (formerly Isoray) develops and manufactures radioactive "seeds" for brachytherapy—the internal irradiation of cancer tumors. This is a high-tech niche in oncology. The chart shows how the market values its unique technology and manufacturing capabilities. The cost per employee reflects the value of its intellectual capital.
%20by%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-platforms&v=1772573833570 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology platforms")
Market capitalization per employee (in thousands of dollars) for the overall market
Perspective Therapeutics develops targeted radiation therapy for cancer using smart molecules to deliver radiation directly to tumor cells. This chart shows a very high market value per employee, reflecting the enormous potential of their precision oncology platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772573833594 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Perspective Therapeutics (CATX)
Perspective Therapeutics (CATX) is a biotech company developing "targeted alpha therapy," a radiation therapy method that delivers radiation directly to cancer cells. This is R&D. This chart shows the "cost" of this cutting-edge science—the negative profit (expense) per scientist.
%20Chart%20Perspective%20Therapeutics%20(CATX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Perspective-Therapeutics-CATX&v=1772573833612 "Company Profit Per Employee (in thousands of dollars) Chart Perspective Therapeutics (CATX)")
Profit per employee (in thousands of dollars) in the market segment - Oncology platforms
Perspective Therapeutics (CATX) specializes in theranostics—an approach that integrates cancer diagnostics and therapy using radiopharmaceuticals. This chart demonstrates the benchmark performance of its biotech staff. It is important for assessing how effectively the CATX scientific team is implementing its unique approach.
%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-platforms&v=1772573833674 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology platforms")
Profit per employee (in thousands of dollars) for the market as a whole
Perspective Therapeutics (CATX) is a biotech company specializing in theranostics—a combination of cancer diagnostics and therapy using radioactive isotopes. This is a complex R&D project. The chart shows the R&D costs (negative profit) per scientist in the effort to develop and commercialize this cutting-edge cancer treatment.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772573833700 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Perspective Therapeutics (CATX)
Perspective Therapeutics develops targeted radiation therapy for cancer. This chart reflects its scientific focus. The lack of revenue per employee is typical for a clinical-stage company investing all its resources in proving the effectiveness of its innovative approach to cancer treatment.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Perspective-Therapeutics-CATX&v=1772573833793 "Sales chart per company employee Perspective Therapeutics (CATX)")
Sales per employee in the market segment - Oncology platforms
Perspective Therapeutics (CATX) is a company specializing in theranostics—a combination of diagnostics and targeted therapy (using radioactive isotopes) for cancer treatment. This chart shows how much revenue (from partnerships) each employee (scientist) generates. It's an indicator of the productivity of their R&D platform.
Sales per employee for the market as a whole
Perspective Therapeutics (CATX) is a clinical-stage radiology company. They develop targeted therapies that deliver radiation (alpha particles) directly to cancer cells. This is an R&D business with no commercial revenue. This graph (close to zero) reflects investments in cutting-edge nuclear medicine: their research staff is working on developing a new class of cancer drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Perspective Therapeutics (CATX)
Perspective Therapeutics (CATX) is a biotech company specializing in radiopharmaceuticals—the use of radioactive isotopes to diagnose and treat cancer. This chart shows bearish bets. The shorts are driven by high risks: the technology is complex, isotope production is unstable, and clinical trials could fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Perspective-Therapeutics-CATX&v=1772573833954 "Short Shares Chart for the Company Perspective Therapeutics (CATX)")
Shares shorted by market segment - Oncology platforms
Perspective Therapeutics (CATX) is a company developing "targeted alpha therapy," a cancer treatment that delivers radioactive isotopes precisely to tumors. This chart shows the odds against the entire biotech sector. The rising odds against the industry reflect investor skepticism about the success of this complex technology and a lack of funding.
Shares shorted by the overall market
Perspective Therapeutics develops cancer treatment platforms. The company's success depends on scientific breakthroughs, not GDP. But when the market is gripped by fear (high values on the chart), investors switch to risk-off mode. Speculative biotechs burning cash, like CATX, are the first to be hit, as their access to financing becomes dramatically more difficult.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Perspective Therapeutics (CATX)
Perspective Therapeutics (formerly Isoray) develops radiopharmaceuticals for cancer treatment. The stock is highly speculative. This chart can soar above 70 on positive R&D news. Oversold levels (<30) often reflect research setbacks, funding concerns, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Perspective-Therapeutics-CATX&v=1772573834138 "RSI 14 indicator chart for the company's stock Perspective Therapeutics (CATX)")
RSI 14 Market Segment - Oncology platforms
Perspective Therapeutics (CATX) is a radiopharmaceutical company developing "targeted alpha therapy"—a method for delivering high-powered radiation directly to cancer cells. This chart illustrates the overall sentiment in the oncology platform sector. It helps separate CATX's momentum from the general "hype" or "disappointment" in this complex field of biotech.
RSI 14 for the overall market
Perspective Therapeutics (CATX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CATX (Perspective Therapeutics)
Perspective Therapeutics (CATX) is a company developing targeted alpha therapy (TAT), a cutting-edge cancer treatment that uses isotopes to precisely destroy tumors. This chart shows the speculative average price target from analysts based on their belief in this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CATX-Perspective-Therapeutics&v=1772573834223 "A chart showing analyst consensus forecasts for the expected stock price. CATX (Perspective Therapeutics)")
The difference between the consensus estimate and the actual stock price CATX (Perspective Therapeutics)
Perspective (CATX) is a biotech company focused on theranostics (treatment and diagnostics). It develops targeted radiotherapeutics that simultaneously find and destroy cancer. This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in this cutting-edge oncology R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CATX-Perspective-Therapeutics&v=1772573834327 "A chart showing the difference between the consensus forecast and the actual stock price. CATX (Perspective Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology platforms
Perspective Therapeutics (CATX) is a radiopharmaceutical company. It develops targeted drugs that deliver alpha emitters (radiation) directly to cancer cells. This chart shows analysts' overall expectations across the oncology sector. It reflects whether experts believe nuclear medicine is the next breakthrough in cancer treatment.
Analysts' consensus forecast for the overall market share price
Perspective Therapeutics is a biotech at the cutting edge of science (radiopharmaceuticals). It's a risky R&D story. This chart of overall market sentiment is important. Optimism = the market is willing to burn money funding unprofitable biotechs with revolutionary potential. Pessimism = "risk aversion," and capital for R&D (like CATX) dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Perspective Therapeutics
Perspective Therapeutics (CATX) is a clinical-stage biotech company at the forefront of oncology—targeted alpha therapy (TAT). They deliver radioactive isotopes directly to cancer cells. This chart represents pure R&D betting. Its valuation reflects the market's faith in their futuristic scientific platform and the data from their early (and very risky) clinical trials.
AKIMA Market Segment Index - Oncology platforms
Perspective Therapeutics (CATX) is a company working at the intersection of cancer diagnostics and therapy (theranostics) using radiopharmaceuticals. This chart shows the average index for the oncology sector. It allows investors to assess how CATX's innovative approach compares to the industry average.
The AKIM Index for the overall market
Perspective Therapeutics is a medical device company developing radiopharmaceuticals for cancer treatment (alpha therapy). This chart, reflecting the market average, provides context. It helps assess how this innovative story in the hot nuclear medicine sector compares to overall economic trends and investor interest.
